Cargando…
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
Autores principales: | Passiglia, Francesco, Novello, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815369/ https://www.ncbi.nlm.nih.gov/pubmed/33489814 http://dx.doi.org/10.21037/tlcr-2019-cnsclc-14 |
Ejemplares similares
-
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020) -
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
por: Ekman, Simon
Publicado: (2020) -
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
por: Matter, Matthias S., et al.
Publicado: (2020) -
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020) -
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)